Universitätsklinikum Ulm

Distale Radiusfraktur: Konservativ versus operativ (2016) Kalbitz M, Gebhard F Journal article Revitalisation of a decellularised xenogenic meniscus implant by cells from human synovial membrane (2016) Tluczynski K, Körber L, Schwarz S, Rotter N, Buchholz R, Breiter R Conference contribution, Abstract of a poster Decellularized xenogenic meniscus as a replacement for meniscal tissue (2016) Körber L, Mauer J, Rösch R, Tluczynski K, Schwarz S, Rotter N, Buchholz R, Breiter R Conference contribution, Abstract of a poster Characterization of a migrative subpopulation of adult human nasoseptal chondrocytes with progenitor cell features and their potential for in vivo cartilage regeneration strategies (2016) Breiter R, Schwarz S, Joos H, Körber L, Brenner RE, Rotter N Journal article, other Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al. Conference contribution The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al. Conference contribution Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution Oral cavity carcinomas as primary manifestation of telomere maintenance disorders (telomeropathies) (2016) Beier F, Schmitt K, Bouillon AS, Hasenbank C, Vankann L, Ambrosch P, Hoffmann T, et al. Conference contribution Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution